Price movement over the last 24 hours
ADMA Biologics Inc vs Hewlett Packard Enterprise Co — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Hewlett Packard Enterprise Co trades at $44.52 (market cap $57.56B). The key difference: Hewlett Packard Enterprise Co is far larger — about 27× ADMA Biologics Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.31% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HPE | |
|---|---|---|
Market Cap | $2.13B | $57.56B |
Sector | Health | Technology |
52-Week High | $20.38 | $56.14 |
52-Week Low | $7.60 | $19.81 |
Enterprise Value | $2.20B | $73.52B |
Dividend Yield | — | 1.31% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
HPE trades at $43.445, up 5.42% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $34.3B in 2025, but net income fell sharply to $57M, pressuring margins. Analysts show a mixed consensus with a $69.69 price target, implying significant upside. The stock faces headwinds from high valuation multiples and volatile cash flows, though AI server demand and dividend payments offer support.
The outlook balances growth from AI infrastructure investments against execution risks and margin pressure. Upside hinges on sustained earnings outperformance and debt management, while downside risks include competitive threats and macroeconomic volatility. Institutional sentiment is cautiously optimistic given the high price target disparity.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →